

Mohsen Sadatsafavi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2595579/publications.pdf>

Version: 2024-02-01

348
papers

22,021
citations

22153

59
h-index

10734

138
g-index

363
all docs

363
docs citations

363
times ranked

20371
citing authors

#	ARTICLE	IF	CITATIONS
1	Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 20-27.	3.2	16
2	A patient decision aid for mild asthma: Navigating a new asthma treatment paradigm. <i>Respiratory Medicine</i> , 2022, 201, 106568.	2.9	11
3	The Hidden and Unchecked Judgement Calls When Using Exacerbation History for Managing COPD. <i>Archivos De Bronconeumologia</i> , 2022, 58, 629-631.	0.8	1
4	Model-Based ROC Curve: Examining the Effect of Case Mix and Model Calibration on the ROC Plot. <i>Medical Decision Making</i> , 2022, 42, 487-499.	2.4	12
5	Barriers and Enablers to Objective Testing for Asthma and COPD in Primary Care. <i>Chest</i> , 2022, 161, 888-905.	0.8	13
6	Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2022, 161, 1320-1329.	0.8	25
7	Benefit-harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease. <i>Thorax</i> , 2022, 77, 1079-1087.	5.6	4
8	Long-Term Natural History of Severe Asthma Exacerbations and Their Impact on the Disease Course. <i>Annals of the American Thoracic Society</i> , 2022, 19, 907-915.	3.2	2
9	Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 962-970.	3.2	5
10	Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 63-78.	3.4	41
11	A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study. <i>Addiction Science & Clinical Practice</i> , 2022, 17, 1.	2.6	1
12	Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1202-1216.e23.	3.8	22
13	Validation of the 4C prediction models to inform care for patients with COVID-19: final steps towards clinical application. <i>Thorax</i> , 2022, 77, 536-536.	5.6	0
14	A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada. <i>Vaccine</i> , 2022, 40, 1047-1053.	3.8	3
15	Uncertainty and the Value of Information in Risk Prediction Modeling. <i>Medical Decision Making</i> , 2022, 42, 661-671.	2.4	3
16	Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. <i>European Respiratory Journal</i> , 2022, 60, 2102571.	6.7	57
17	Derivation and validation of the UCAP-Q case-finding questionnaire to detect undiagnosed asthma and COPD. <i>European Respiratory Journal</i> , 2022, 60, 2103243.	6.7	6
18	Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2022, 161, 1594-1597.	0.8	4

#	ARTICLE	IF	CITATIONS
19	A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies. <i>BMC Pulmonary Medicine</i> , 2022, 22, 148.	2.0	5
20	External validation of lung function predictions in real-world cohorts of COPD. <i>Respiratory Medicine</i> , 2022, 198, 106859.	2.9	1
21	Disease burden in individuals with symptomatic undiagnosed asthma or COPD. <i>Respiratory Medicine</i> , 2022, 200, 106917.	2.9	4
22	Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 203-215.	2.1	7
23	Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 149-158.	10.7	46
24	The reporting of observational studies of drug effectiveness and safety: recommendations to extend existing guidelines. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8.	2.4	2
25	Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?. <i>European Respiratory Journal</i> , 2021, 57, 2002122.	6.7	21
26	Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. <i>Journal of Asthma</i> , 2021, 58, 514-522.	1.7	30
27	A conceptual model of functional health literacy to improve chronic airway disease outcomes. <i>BMC Public Health</i> , 2021, 21, 252.	2.9	7
28	Treatment Initiation in Patients with Interstitial Lung Disease in Canada. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1661-1668.	3.2	4
29	The economics of precision health: preventing air pollution-induced exacerbation in asthma. <i>ERJ Open Research</i> , 2021, 7, 00790-2020.	2.6	2
30	Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 14-23.	5.6	32
31	Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. <i>Drug Safety</i> , 2021, 44, 467-478.	3.2	8
32	The Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and the Heterogeneity of Risk Factors in the Canadian Population: Results from the Canadian Obstructive Lung Disease (COLD) Study. <i>International Journal of COPD</i> , 2021, Volume 16, 305-320.	2.3	16
33	Are COPD Prescription Patterns Aligned with Guidelines? Evidence from a Canadian Population-Based Study. <i>International Journal of COPD</i> , 2021, Volume 16, 751-759.	2.3	6
34	Potential Severe Asthma Hidden in UK Primary Care. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1612-1623.e9.	3.8	42
35	Trends in oral corticosteroids use in severe asthma: a 14-year population-based study. <i>Respiratory Research</i> , 2021, 22, 103.	3.6	8
36	Impact of the 13-valent pneumococcal conjugate vaccine on acute otitis media and acute sinusitis epidemiology in British Columbia, Canada. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2419-2427.	3.0	9

#	ARTICLE	IF	CITATIONS
37	Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2255-2261.	3.8	76
38	Specialist Care in Individuals with Asthma Who Required Hospitalization: A Retrospective Population-Based Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3686-3696.	3.8	4
39	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. <i>Respiratory Research</i> , 2021, 22, 202.	3.6	5
40	Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 266-271.e2.	2.9	22
41	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3997-4004.	3.8	74
42	Pan-Canadian standards for severe asthma in electronic medical records. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2021, 5, 391-399.	0.5	2
43	An Integrated Framework to Conceptualize and Develop the Vancouver Airways Health Literacy Tool (VAHLT). <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8646.	2.6	6
44	Eosinophilic and Noneosinophilic Asthma. <i>Chest</i> , 2021, 160, 814-830.	0.8	109
45	Moving beyond AUC: decision curve analysis for quantifying net benefit of risk prediction models. <i>European Respiratory Journal</i> , 2021, 58, 2101186.	6.7	17
46	Personalising add-on treatment with inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a benefit-harm modelling study. <i>The Lancet Digital Health</i> , 2021, 3, e644-e653.	12.3	8
47	The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada. <i>Allergy, Asthma and Clinical Immunology</i> , 2021, 17, 108.	2.0	8
48	Development of a conceptual model of childhood asthma to inform asthma prevention policies. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000881.	3.0	1
49	Impact of Socioeconomic Status on Adult Patients with Asthma: A Population-Based Cohort Study from UK Primary Care. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1375-1388.	3.4	13
50	An Individualized Prediction Model for Long-term Lung Function Trajectory and Risk of COPD in the General Population. <i>Chest</i> , 2020, 157, 547-557.	0.8	15
51	Socioeconomic status at diagnosis influences the incremental direct medical costs of systemic lupus erythematosus: A longitudinal population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 77-83.	3.4	8
52	Bridging the gap: Key informants' perspectives on patient barriers in asthma and COPD self-management and possible solutions. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 106-114.	0.5	5
53	Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1367-1377.e4.	2.9	14
54	International Severe Asthma Registry. <i>Chest</i> , 2020, 157, 805-814.	0.8	38

#	ARTICLE	IF	CITATIONS
55	<p>Patient-Reported Outcome Measures (PROMs) to Support Adherence to Falls Prevention Clinic Recommendations: A Qualitative Study</p>. Patient Preference and Adherence, 2020, Volume 14, 2105-2121.	1.8	1
56	The burden of exacerbations in mild asthma: a systematic review. ERJ Open Research, 2020, 6, 00359-2019.	2.6	33
57	Asthma exacerbations and worsenings in patients aged 1â€“75 years with add-on tiotropium treatment. Npj Primary Care Respiratory Medicine, 2020, 30, 38.	2.6	5
58	Understanding resource utilization and mortality in COPD to support policy making: A microsimulation study. PLoS ONE, 2020, 15, e0236559.	2.5	0
59	International severe asthma registry (ISAR): protocol for a global registry. BMC Medical Research Methodology, 2020, 20, 212.	3.1	29
60	<p>The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline</p>. International Journal of COPD, 2020, Volume 15, 1909-1918.	2.3	17
61	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respiratory Research, 2020, 21, 322.	3.6	18
62	Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study. Respiratory Research, 2020, 21, 118.	3.6	13
63	Predicting Severe Chronic Obstructive Pulmonary Disease Exacerbations. Developing a Population Surveillance Approach with Administrative Data. Annals of the American Thoracic Society, 2020, 17, 1069-1076.	3.2	21
64	Looking at the COPD spectrum through â€œPRISMâ€œ. European Respiratory Journal, 2020, 55, 1902217.	6.7	15
65	Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax, 2020, 75, 744-753.	5.6	32
66	Avoiding immortal time bias in observational studies. European Respiratory Journal, 2020, 55, 1902494.	6.7	0
67	The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study. Lancet Respiratory Medicine, the, 2020, 8, 1013-1021.	10.7	72
68	Effects of Î²2â€œAdrenergic Agonists on Risk of Parkinson's Disease in COPD: A Populationâ€œBased Study. Pharmacotherapy, 2020, 40, 408-415.	2.6	7
69	Response. Chest, 2020, 157, 738-739.	0.8	0
70	Validation and Utility Testing of Clinical Prediction Models. JAMA - Journal of the American Medical Association, 2020, 324, 235.	7.4	70
71	The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK. Respiratory Medicine, 2020, 171, 106079.	2.9	15
72	Costs of Workplace Productivity Loss in Patients with Connective Tissue Diseaseâ€œassociated Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1077-1084.	3.2	5

#	ARTICLE	IF	CITATIONS
73	A threshold-free summary index for quantifying the capacity of covariates to yield efficient treatment rules. <i>Statistics in Medicine</i> , 2020, 39, 1362-1373.	1.6	1
74	Targeted management of severe asthma: Developing a Canadian approach. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 124-132.	0.5	1
75	Asthma and COPD patients' perceived link between health literacy core domains and self-management of their condition. <i>Patient Education and Counseling</i> , 2020, 103, 1415-1421.	2.2	8
76	Identification and definition of asthma-COPD overlap: The CanCOLD study. <i>Respirology</i> , 2020, 25, 836-849.	2.3	45
77	Effects of long-term inhaled corticosteroid treatment on fragility fractures in older women: the Manitoba BMD registry study. <i>Osteoporosis International</i> , 2020, 31, 1155-1162.	3.1	1
78	Healthcare system encounters before COPD diagnosis: a registry-based longitudinal cohort study. <i>Thorax</i> , 2020, 75, 108-115.	5.6	5
79	Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs. <i>European Respiratory Journal</i> , 2020, 55, 1902048.	6.7	31
80	–Development and Pretesting of a New Functional-Based Health Literacy Measurement Tool for Chronic Obstructive Pulmonary Disease (COPD) and Asthma Management–. <i>International Journal of COPD</i> , 2020, Volume 15, 613-625.	2.3	10
81	Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis. <i>Chest</i> , 2020, 158, 479-490.	0.8	21
82	Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, e56-e69.	5.6	202
83	Population-based case-finding to identify subjects with undiagnosed asthma or COPD. <i>European Respiratory Journal</i> , 2020, 55, 2000024.	6.7	23
84	Assessing factors influencing smoking and smoking cessation within Chinese communities in the Greater Vancouver Area: A qualitative exploratory study. <i>Tobacco Prevention and Cessation</i> , 2020, 6, 1-14.	0.4	5
85	Testing Clinical Prediction Models–Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2000.	7.4	0
86	A pilot randomized controlled trial on the impact of text messaging check-ins and a web-based asthma action plan versus a written action plan on asthma exacerbations. <i>Journal of Asthma</i> , 2019, 56, 897-909.	1.7	9
87	Effect of short-term oral prednisone therapy on blood gene expression: a randomised controlled clinical trial. <i>Respiratory Research</i> , 2019, 20, 176.	3.6	4
88	Impaired Sleep Quality in COPD Is Associated With Exacerbations. <i>Chest</i> , 2019, 156, 852-863.	0.8	47
89	–Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey–. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 183-194.	3.4	23
90	GINA 2019: a fundamental change in asthma management. <i>European Respiratory Journal</i> , 2019, 53, 1901046.	6.7	277

#	ARTICLE	IF	CITATIONS
91	The Challenges and Opportunities of Maximizing the Benefits of Severe Asthma Registries. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1469-1470.	3.8	1
92	The effects of marijuana smoking on lung function in older people. <i>European Respiratory Journal</i> , 2019, 54, 1900826.	6.7	32
93	<p>Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2003-2013.	2.3	16
94	Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. <i>Clinical Therapeutics</i> , 2019, 41, 2041-2056.e5.	2.5	102
95	Triple therapy in a single inhaler: a new option for uncontrolled asthma. <i>Lancet, The</i> , 2019, 394, 1690-1692.	13.7	8
96	Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada. <i>Medical Decision Making</i> , 2019, 39, 152-167.	2.4	10
97	Introduction to precision medicine in COPD. <i>European Respiratory Journal</i> , 2019, 53, 1802460.	6.7	37
98	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2019, 156, 887-895.	0.8	14
99	A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions. <i>Value in Health</i> , 2019, 22, 1070-1082.	0.3	8
100	Transparency in Decision Modelling: What, Why, Who and How?. <i>Pharmacoeconomics</i> , 2019, 37, 1355-1369.	3.3	28
101	The Projected Economic and Health Burden of Uncontrolled Asthma in the United States. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1102-1112.	5.6	178
102	Lowering the P Value Threshold. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1532.	7.4	5
103	Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries. <i>Emerging Infectious Diseases</i> , 2019, 25, 661-671.	4.3	19
104	Extent, trends, and determinants of controller/reliever balance in mild asthma: a 14-year population-based study. <i>Respiratory Research</i> , 2019, 20, 44.	3.6	1
105	Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study. <i>European Respiratory Journal</i> , 2019, 53, 1801257.	6.7	46
106	Precision health: treating the individual patient with chronic obstructive pulmonary disease. <i>Medical Journal of Australia</i> , 2019, 210, 424-428.	1.7	6
107	Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study. <i>BMJ Open</i> , 2019, 9, e023714.	1.9	23
108	Direct costs of overdiagnosed asthma: a longitudinal, population-based cohort study in British Columbia, Canada. <i>BMJ Open</i> , 2019, 9, e031306.	1.9	7

#	ARTICLE	IF	CITATIONS
109	Vitamin D in the prevention of exacerbations of asthma in preschoolers (DIVA): protocol for a multicentre randomised placebo-controlled triple-blind trial. <i>BMJ Open</i> , 2019, 9, e033075.	1.9	5
110	Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study. <i>Thorax</i> , 2019, 74, 1113-1119.	5.6	27
111	Cholinergic synapse pathway gene polymorphisms associated with allergen-induced late asthmatic responses. <i>ERJ Open Research</i> , 2019, 5, 00107-2019.	2.6	4
112	Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis. <i>Immunotherapy</i> , 2019, 11, 1491-1505.	2.0	6
113	Baseline characteristics and comorbidities in the Canadian REgistry for Pulmonary Fibrosis. <i>BMC Pulmonary Medicine</i> , 2019, 19, 223.	2.0	52
114	<p>Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma</p>. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 401-413.	3.4	28
115	Making sense of cost-effectiveness analyses in respiratory medicine: a practical guide for non-health economists. <i>European Respiratory Journal</i> , 2019, 53, 1801816.	6.7	16
116	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 46-59.	10.7	216
117	Sputum Microbiome Is Associated with 1-Year Mortality after Chronic Obstructive Pulmonary Disease Hospitalizations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1205-1213.	5.6	95
118	A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma. <i>Journal of Asthma</i> , 2019, 56, 1334-1346.	1.7	33
119	Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 578-588.e2.	3.8	39
120	Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. <i>American Journal of Kidney Diseases</i> , 2019, 73, 39-50.	1.9	11
121	Risk of Incident Chronic Obstructive Pulmonary Disease in Rheumatoid Arthritis: A Populationâ€Based Cohort Study. <i>Arthritis Care and Research</i> , 2019, 71, 602-610.	3.4	28
122	Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and SjÃ¶gren's Syndrome: A General Populationâ€Based Study. <i>Arthritis Care and Research</i> , 2019, 71, 142-154.	3.4	11
123	Probabilistic Return-on-Investment Analysis of Single-Family Versus Open-Bay Rooms in Neonatal Intensive Care Unitsâ€Synthesis and Evaluation of Early Evidence on Nosocomial Infections, Length of Stay, and Direct Cost of Care. <i>Journal of Intensive Care Medicine</i> , 2019, 34, 115-125.	2.8	9
124	Asthma control in preschoolers: a strong predictor of long-term morbidity. , 2019, , .		1
125	Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective. , 2019, , .		0
126	Late Breaking Abstract - Asthma control in preschool and subsequent disease remission. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
127	Effect of COPD exacerbations on early lung function decline under maintenance therapy: blood eosinophil count asbiomarker. , 2019, , .		0
128	Effects of Regular Use of ÅŒ2-Adrenergic Receptor Agonists on the Risk of Parkinsonâ€™s Disease in Patients with COPD. , 2019, , .		0
129	Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213023.	0.9	22
130	The projected economic and health burden of sub-optimal asthma control in Canada. Respiratory Medicine, 2018, 138, 7-12.	2.9	22
131	The Impact of Care Specialty on Survival-Adjusted Medical Costs of COPD Patients After a Hospitalization: a longitudinal analysis. Journal of General Internal Medicine, 2018, 33, 1528-1535.	2.6	2
132	Response. Chest, 2018, 153, 578-579.	0.8	0
133	The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. European Respiratory Journal, 2018, 51, 1701488.	6.7	25
134	Predictors of inappropriate and excessive use of reliever medications in asthma: a 16-year population-based study. BMC Pulmonary Medicine, 2018, 18, 33.	2.0	27
135	Patients as research partners in chronic obstructive pulmonary disease and asthma research: Priorities, challenges and recommendations from asthma and COPD patients. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 138-146.	0.5	7
136	Airway diseases and health literacy (HL) measurement tools: A systematic review to inform respiratory research and practice. Patient Education and Counseling, 2018, 101, 596-618.	2.2	18
137	Patterns of Biologics Utilization and Discontinuation Before and During Pregnancy in Women With Autoimmune Diseases: A Populationâ€™Based Cohort Study. Arthritis Care and Research, 2018, 70, 979-986.	3.4	23
138	Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respiratory Medicine,the, 2018, 6, 51-64.	10.7	220
139	Novel Blood-based Transcriptional Biomarker Panels Predict the Late-Phase Asthmatic Response. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 450-462.	5.6	18
140	Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma. Allergy International, 2018, 67, 266-272.	3.3	24
141	Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD. International Journal of COPD, 2018, Volume 13, 3983-3995.	2.3	12
142	Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study. Archives of Osteoporosis, 2018, 13, 116.	2.4	16
143	Tiotropium add-on to inhaled corticosteroids versus addition of long-acting Î²2-agonists for adults with asthma. Respiratory Medicine, 2018, 143, 82-90.	2.9	21
144	Asthma in low-income and middle-income countries: an urgent call to action. Thorax, 2018, 73, 898-899.	5.6	4

#	ARTICLE	IF	CITATIONS
145	Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 2486-2496.	27.0	1,253
146	Inhaled Combined Budesonide“Formoterol as Needed in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 1865-1876.	27.0	453
147	As-Needed Budesonide“Formoterol versus Maintenance Budesonide in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 1877-1887.	27.0	368
148	Long-Term Trajectories of Mild Asthma in Adulthood and Risk Factors of Progression. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2024-2032.e5.	3.8	27
149	Health literacy in chronic disease management: a matter of interaction. <i>Journal of Clinical Epidemiology</i> , 2018, 102, 134-138.	5.0	95
150	Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12—years and older with an eosinophilic phenotype. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 669-676.	3.1	6
151	Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study. <i>Lupus</i> , 2018, 27, 1247-1258.	1.6	10
152	Phenotyping COPD exacerbations using imaging and blood-based biomarkers. <i>International Journal of COPD</i> , 2018, Volume 13, 217-229.	2.3	16
153	The diagnostic performance of patient symptoms in screening for COPD. <i>Respiratory Research</i> , 2018, 19, 147.	3.6	5
154	Asthma is not associated with the need for surgery in Crohn’s disease when controlling for smoking status: a population-based cohort study. <i>Clinical Epidemiology</i> , 2018, Volume 10, 831-840.	3.0	1
155	History of respiratory medicine at University of British Columbia. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2018, 2, 53-57.	0.5	0
156	Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Respiratory Research</i> , 2018, 19, 26.	3.6	22
157	Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 3.	1.5	37
158	Relative impact characteristic curve: a graphical tool to visualize and quantify the clinical utility and population-level consequences of implementing markers. <i>Annals of Epidemiology</i> , 2018, 28, 717-723.e3.	1.9	3
159	Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. <i>European Respiratory Journal</i> , 2018, 52, 1800936.	6.7	173
160	Between-Visit Variability in FEV1 as a Diagnostic Test for Asthma in Adults. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1039-1046.	3.2	7
161	The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology. <i>PLoS ONE</i> , 2018, 13, e0191243.	2.5	21
162	Drivers of respiratory symptoms in COPD patients. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
163	The discriminatory capacity of symptoms to distinguish undiagnosed COPD from non-COPD. , 2018, , .		0
164	The Projected Epidemic of Chronic Obstructive Pulmonary Disease Hospitalizations over the Next 15 Years. A Population-based Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 287-291.	5.6	98
165	Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma. JAMA - Journal of the American Medical Association, 2017, 317, 269.	7.4	336
166	The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given as needed™ in mild asthma: study protocols for two randomised controlled trials. Trials, 2017, 18, 12.	1.6	30
167	The Impact of Statin Drug Use on All-Cause Mortality in Patients With COPD. Chest, 2017, 152, 486-493.	0.8	43
168	Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment. Value in Health, 2017, 20, 969-975.	0.3	22
169	Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine, the, 2017, 5, 568-576.	10.7	99
170	Stability of Asthma Symptom Control in a Longitudinal Study of Mild-Moderate Asthmatics. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1663-1670.e5.	3.8	9
171	Asthma Is Associated With Subsequent Development of Inflammatory Bowel Disease: A Population-based Case-Control Study. Clinical Gastroenterology and Hepatology, 2017, 15, 1405-1412.e3.	4.4	34
172	Enumerateblood – an R package to estimate the cellular composition of whole blood from Affymetrix Gene ST gene expression profiles. BMC Genomics, 2017, 18, 43.	2.8	7
173	Modifying the trajectory of asthma—are there lessons from the use of biologics in rheumatology?. Lancet, The, 2017, 389, 1082-1084.	13.7	3
174	Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review. Respiriology, 2017, 22, 61-70.	2.3	25
175	Crowdfunding for respiratory research: a new frontier for patient and public engagement?. European Respiratory Journal, 2017, 50, 1701333.	6.7	3
176	Emerging interleukin receptor antagonists for the treatment of asthma. Expert Opinion on Emerging Drugs, 2017, 22, 275-283.	2.4	1
177	The impact of inappropriate use of short acting beta agonists in asthma. Respiratory Medicine, 2017, 131, 135-140.	2.9	61
178	Do community demographics, environmental characteristics and access to care affect risks of developing ACOS and mortality in people with asthma?. European Respiratory Journal, 2017, 50, 1700644.	6.7	5
179	Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study. BMJ Open, 2017, 7, e015108.	1.9	20
180	Work productivity loss in mild to moderate COPD: lessons learned from the CanCOLD study. European Respiratory Journal, 2017, 50, 1701154.	6.7	9

#	ARTICLE	IF	CITATIONS
181	Asthma patient education, the overlooked aspect of disease management. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 43-45.	0.5	1
182	Excess economic burden of comorbidities in COPD: a 15-year population-based study. European Respiratory Journal, 2017, 50, 1700393.	6.7	44
183	Improving precision in the prediction of asthma exacerbations. Lancet Respiratory Medicine, the, 2017, 5, 539-540.	10.7	3
184	B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulmonary Medicine, 2017, 17, 11.	2.0	43
185	Mortality and acute exacerbation of COPD: a pilot study on the influence of myocardial injury. European Respiratory Journal, 2017, 49, 1700096.	6.7	7
186	Has Asthma Medication Use Caught Up With the Evidence?. Chest, 2017, 151, 612-618.	0.8	23
187	A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease. Value in Health, 2017, 20, 152-162.	0.3	22
188	Ten-year trends in direct costs of asthma: a population-based study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 291-299.	5.7	16
189	Asthma control and productivity loss in those with work-related asthma: A population-based study. Journal of Asthma, 2017, 54, 537-542.	1.7	7
190	Biomarker Development in COPD. Chest, 2017, 151, 455-467.	0.8	36
191	The impact of a history of asthma on long-term outcomes of people with newly diagnosed chronic obstructive pulmonary disease: A population study. Journal of Allergy and Clinical Immunology, 2017, 139, 835-843.	2.9	9
192	Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. Biomarker Insights, 2017, 12, 117727191773030.	2.5	4
193	Recognition and management of severe asthma: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 199-221.	0.5	42
194	Impact of a COPD comprehensive case management program on hospital length of stay and readmission rates. International Journal of COPD, 2017, Volume 12, 961-971.	2.3	38
195	Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada. PLoS ONE, 2017, 12, e0186778.	2.5	15
196	The neglected burden of tuberculosis disease among health workers: a decade-long cohort study in South Africa. BMC Infectious Diseases, 2017, 17, 547.	2.9	17
197	Concurrent physician-diagnosed asthma and chronic obstructive pulmonary disease: A population study of prevalence, incidence and mortality. PLoS ONE, 2017, 12, e0173830.	2.5	27
198	C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations. PLoS ONE, 2017, 12, e0174063.	2.5	14

#	ARTICLE	IF	CITATIONS
199	Perceived Barriers to Asthma Therapy in Ethno-Cultural Communities: The Role of Culture, Beliefs and Social Support. <i>Health</i> , 2017, 09, 1029-1046.	0.3	7
200	Asthma Is Not Associated With the Need for Surgery in Crohn's Disease When Controlling for Smoking Status: A Population-Based Cohort Study. <i>American Journal of Gastroenterology</i> , 2017, 112, S1476.	0.4	0
201	History of Asthma in Patients with Chronic Obstructive Pulmonary Disease. A Comparative Study of Economic Burden. <i>Annals of the American Thoracic Society</i> , 2016, 13, 188-196.	3.2	16
202	Attitude to health risk in the Canadian population: a cross-sectional survey. <i>CMAJ Open</i> , 2016, 4, E284-E291.	2.4	9
203	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-7.	1.6	45
204	The impact of comorbidities on productivity loss in asthma patients. <i>Respiratory Research</i> , 2016, 17, 106.	3.6	14
205	Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma. <i>PLoS ONE</i> , 2016, 11, e0146003.	2.5	56
206	Saving in medical costs by achieving guideline-based asthma symptom control: a population-based study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 371-377.	5.7	22
207	The asthma control in daily practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 907-909.	5.7	2
208	Excess medical costs in patients with asthma and the role of comorbidity. <i>European Respiratory Journal</i> , 2016, 48, 1584-1592.	6.7	33
209	Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 502.	1.6	17
210	Author response to commentary on article "Intensive care unit-acquired infections: It is not only about the number of patients per room". <i>Journal of Critical Care</i> , 2016, 34, 124.	2.2	0
211	Less chaos in the prognosis of asthma-chronic obstructive lung disease overlap. <i>Lancet Respiratory Medicine</i> , 2016, 4, 421-422.	10.7	0
212	Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1051-1059.	2.9	122
213	Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , 2016, 388, 2128-2141.	13.7	1,070
214	Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β_2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. <i>Lancet</i> , 2016, 388, 2115-2127.	13.7	1,050
215	Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. <i>Cmaj</i> , 2016, 188, 1004-1011.	2.0	38
216	Level of Asthma Controller Therapy Before Admission to the Hospital. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 877-883.	3.8	11

#	ARTICLE	IF	CITATIONS
217	The Association Between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model. <i>American Journal of Epidemiology</i> , 2016, 184, 681-689.	3.4	31
218	Culturally Specific Evaluation of Inhaler Techniques in Asthma. <i>Respiratory Care</i> , 2016, 61, 1588-1596.	1.6	14
219	Predictors of hospitalization of tuberculosis patients in Montreal, Canada: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2016, 16, 679.	2.9	12
220	Influences of Socioeconomic Status on Costs of Asthma Under Universal Health Coverage. <i>Medical Care</i> , 2016, 54, 789-795.	2.4	16
221	The COPD Assessment Test. <i>Chest</i> , 2016, 150, 1069-1079.	0.8	11
222	Do cost savings from reductions in nosocomial infections justify additional costs of single-bed rooms in intensive care units? A simulation case study. <i>Journal of Critical Care</i> , 2016, 31, 194-200.	2.2	16
223	Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 409-418.	2.1	51
224	The Emerging Role of Health Literacy in Chronic Disease Management: The Response to a Call for Action in Canada. <i>Population Health Management</i> , 2016, 19, 230-231.	1.7	8
225	Progression from Asthma to Chronic Obstructive Pulmonary Disease. Is Air Pollution a Risk Factor?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 429-438.	5.6	110
226	Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 285-298.	5.6	110
227	The global economic burden of asthma and chronic obstructive pulmonary disease. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 11-23.	1.2	163
228	The natural history of severe asthma and influences of early risk factors: a population-based cohort study. <i>Thorax</i> , 2016, 71, 267-275.	5.6	45
229	COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry. <i>PLoS ONE</i> , 2016, 11, e0161129.	2.5	19
230	Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0166745.	2.5	63
231	Achieving asthma control: Providing a framework for clinicians. <i>Annals of Thoracic Medicine</i> , 2016, 11, 1.	1.8	1
232	Interaction effect of psychological distress and asthma control on productivity loss?. <i>European Respiratory Journal</i> , 2015, 45, 1557-1565.	6.7	18
233	One-year outcomes of inhaled controller therapies added to systemic corticosteroids after asthma-related hospital discharge. <i>Respiratory Medicine</i> , 2015, 109, 320-328.	2.9	7
234	Assessing beliefs and risk perceptions on smoking and smoking cessation in immigrant Chinese adult smokers residing in Vancouver, Canada: a cross-sectional study. <i>BMJ Open</i> , 2015, 5, e006435-e006435.	1.9	18

#	ARTICLE	IF	CITATIONS
235	COPD. Chest, 2015, 147, 868-869.	0.8	1
236	Ten-Year Trends in Direct Costs of COPD. Chest, 2015, 148, 640-646.	0.8	66
237	Bronchial thermoplasty in asthma: 2-year follow-up using optical coherence tomography. European Respiratory Journal, 2015, 46, 859-862.	6.7	49
238	Airway diseases and inflammatory bowel diseases: is it something in the air (pollution)?. European Respiratory Journal, 2015, 46, 287-288.	6.7	3
239	Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respiratory Medicine, the, 2015, 3, 631-639.	10.7	425
240	Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea. Medical Decision Making, 2015, 35, 671-682.	2.4	9
241	Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study. Thorax, 2015, 70, 822-829.	5.6	178
242	Quality of Life and Asthma Symptom Control: Room for Improvement in Care and Measurement. Value in Health, 2015, 18, 1043-1049.	0.3	23
243	The added effect of comorbidity on health-related quality of life in patients with asthma. Quality of Life Research, 2015, 24, 2507-2517.	3.1	26
244	Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis. Journal of Allergy and Clinical Immunology, 2015, 136, 914-922.	2.9	58
245	Current and emerging treatments for severe asthma. Journal of Thoracic Disease, 2015, 7, E522-5.	1.4	9
246	Chronic Disease Management: A Proving Ground for Health Literacy. Population Health Management, 2014, 17, 321-323.	1.7	7
247	Heterogeneity's ruses: the neglected role of between-individual variability in longitudinal studies of COPD exacerbations. Thorax, 2014, 69, 1043-1044.	5.6	6
248	Exacerbations in non-COPD patients: truth or myth? authors' response. Thorax, 2014, 69, 1050.2-1051.	5.6	0
249	The effect of weekly text-message communication on treatment completion among patients with latent tuberculosis infection: study protocol for a randomised controlled trial (WelTel LTBI). BMJ Open, 2014, 4, e004362.	1.9	22
250	Long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease. The Cochrane Library, 2014, , .	2.8	4
251	The Preventable Burden of Productivity Loss Due to Suboptimal Asthma Control. Chest, 2014, 145, 787-793.	0.8	68
252	Dispensation of long-acting β agonists with or without inhaled corticosteroids, and risk of asthma-related hospitalisation: a population-based study. Thorax, 2014, 69, 328-334.	5.6	16

#	ARTICLE	IF	CITATIONS
253	The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis - a case study of pharmacotherapies for moderate to severe COPD. <i>Cost Effectiveness and Resource Allocation</i> , 2014, 12, 8.	1.5	12
254	Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 488.	1.6	15
255	Does Culture or Illness Change a Smoker's Perspective on Cessation?. <i>American Journal of Health Behavior</i> , 2014, 38, 657-667.	1.4	8
256	Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. <i>New England Journal of Medicine</i> , 2014, 371, 1198-1207.	27.0	1,807
257	Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes. <i>Pharmacoeconomics</i> , 2014, 32, 995-1004.	3.3	10
258	Incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods. <i>Trials</i> , 2014, 15, 201.	1.6	5
259	COST-effectiveness of salmeterol/fluticasone propionate combination (AdvairÂ®) in uncontrolled asthma in Canada. <i>Respiratory Medicine</i> , 2014, 108, 1292-1302.	2.9	12
260	Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. <i>New England Journal of Medicine</i> , 2014, 370, 2102-2110.	27.0	668
261	Economic and health effect of full adherence to controllerÂ®therapy in adults with uncontrolled asthma: AÂ®simulation study. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 908-915.e3.	2.9	48
262	Elevated risk of chronic obstructive pulmonary disease in systemic lupus erythematosus: a population-based study. <i>Arthritis Research and Therapy</i> , 2014, 16, A34.	3.5	0
263	The Need for Humanomics in the Era of Genomics and the Challenge of Chronic Disease Management. <i>Chest</i> , 2014, 146, 10-12.	0.8	23
264	The importance of measuring asthma control in emerging economies [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 254-254.	1.2	2
265	A Quantitative Benefit-Risk Analysis of Isoniazid for Treatment of Latent Tuberculosis Infection Using Incremental Benefit Framework. <i>Value in Health</i> , 2013, 16, 66-75.	0.3	9
266	Need for Speed: An Efficient Algorithm for Calculation of Single-Parameter Expected Value of Partial Perfect Information. <i>Value in Health</i> , 2013, 16, 438-448.	0.3	27
267	Post-hospital syndrome in adults with asthma: a case-crossover study. <i>Allergy, Asthma and Clinical Immunology</i> , 2013, 9, 49.	2.0	5
268	The Humanistic And Economic Impact Of Following Evidence-Based Asthma Controller Therapy: A Simulation Study. <i>Value in Health</i> , 2013, 16, A235.	0.3	1
269	Comparative outcomes of leukotriene receptor antagonists and long-acting Î²2-agonists as add-on therapy in asthmatic patients: A population-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 63-69.	2.9	19
270	Predicting Lung Transplant Waitlist Survival with the Lung Allocation Score in British Columbia, Canada. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S168-S169.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Associations of Ambient Air Pollution with Chronic Obstructive Pulmonary Disease Hospitalization and Mortality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 721-727.	5.6	234
272	TWO-LEVEL RESAMPLING AS A NOVEL METHOD FOR THE CALCULATION OF THE EXPECTED VALUE OF SAMPLE INFORMATION IN ECONOMIC TRIALS. <i>Health Economics (United Kingdom)</i> , 2013, 22, 877-882.	1.7	8
273	Complementary and alternative asthma treatments and their association with asthma control: a population-based study. <i>BMJ Open</i> , 2013, 3, e003360.	1.9	39
274	TNF α antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. <i>Thorax</i> , 2013, 68, 142-148.	5.6	83
275	Costs and Health Outcomes Associated With Primary vs Secondary Care After an Asthma-Related Hospitalization. <i>Chest</i> , 2013, 144, 428-435.	0.8	16
276	Response to "Marginal Costs of Hospital-Acquired Conditions: Information for Priority-Setting for Patient Safety Programmes and Research" TM , Jackson et al., <i>Journal of Health Services Research & Policy</i> 2011;16:141-6. <i>Journal of Health Services Research and Policy</i> , 2012, 17, 127-127.	1.7	1
277	Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1524-1529.	0.9	718
278	Asthma Control In A Random Sample Of Canadian Asthma Patients. , 2012, , .		0
279	Is Surgical Fixation for Stress-Positive Unstable Ankle Fractures Cost Effective? Results of a Multicenter Randomized Control Trial. <i>Journal of Orthopaedic Trauma</i> , 2012, 26, 652-658.	1.4	27
280	Use Of Complementary And Alternative Therapies In Patients With Asthma: Preliminary Results From A Prospective Study. , 2012, , .		0
281	Effectiveness of Educational Interventions on Asthma Self-Management in Punjabi and Chinese Asthma Patients: A Randomized Controlled Trial. <i>Journal of Asthma</i> , 2012, 49, 542-551.	1.7	59
282	The "Lost NNT" can be used to represent uncertainty surrounding number needed to treat. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 863-868.	5.0	1
283	Economic and Humanistic Burden of External Genital Warts. <i>Pharmacoeconomics</i> , 2012, 30, 1-16.	3.3	34
284	Future Impact of Various Interventions on the Burden of COPD in Canada: A Dynamic Population Model. <i>PLoS ONE</i> , 2012, 7, e46746.	2.5	32
285	Trends in Asthma-Related Direct Medical Costs from 2002 to 2007 in British Columbia, Canada: A Population Based-Cohort Study. <i>PLoS ONE</i> , 2012, 7, e50949.	2.5	59
286	Safety Of Long-Acting Beta Agonists (LABA) With Or Without Inhaled Corticosteroids In Asthma. , 2012, , .		0
287	Low-Molecular-Weight Heparin Versus Unfractionated Heparin for Prophylaxis of Venous Thromboembolism in Medicine Patients" A Pharmacoeconomic Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 454-465.	1.7	12
288	Health Literacy, Language, and Ethnicity-Related Factors in Newcomer Asthma Patients to Canada: A Qualitative Study. <i>Journal of Immigrant and Minority Health</i> , 2011, 13, 315-322.	1.6	52

#	ARTICLE	IF	CITATIONS
289	Secular decreases in fracture rates 1986–2006 for Manitoba, Canada: a population-based analysis. <i>Osteoporosis International</i> , 2011, 22, 2137-2143.	3.1	59
290	Targeting lung attacks. <i>Thorax</i> , 2011, 66, 365-366.	5.6	35
291	Pulmonary function testing in the Emergency Department and medications prescribed at discharge: results of the Multinational Acute asthma Management, Burden, and Outcomes (MAMBO) study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2010, 19, 155-162.	2.3	8
292	A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1172-1180.	1.9	12
293	An Ounce of Prevention Is Worth a Pound of Cure: A Cost-Effectiveness Analysis of Incidentally Detected Aneurysms in Functional MRI Research. <i>Value in Health</i> , 2010, 13, 761-769.	0.3	10
294	Direct Health Care Costs Associated with Asthma in British Columbia. <i>Canadian Respiratory Journal</i> , 2010, 17, 74-80.	1.6	122
295	Canadian Thoracic Society Asthma Committee Commentary on Long-Acting Beta-2 Agonist Use for Asthma in Canada. <i>Canadian Respiratory Journal</i> , 2010, 17, 57-58.	1.6	11
296	Canadian Thoracic Society Asthma Management Continuum – 2010 Consensus Summary for Children Six Years of Age and Over, and Adults. <i>Canadian Respiratory Journal</i> , 2010, 17, 15-24.	1.6	163
297	Current recommendations for the treatment of mild asthma. <i>Journal of Asthma and Allergy</i> , 2010, 3, 169.	3.4	23
298	A statistical method was used for the meta-analysis of tests for latent TB in the absence of a gold standard, combining random-effect and latent-class methods to estimate test accuracy. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 257-269.	5.0	36
299	Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. <i>Lancet, The</i> , 2010, 376, 1838-1845.	13.7	1,098
300	Asthma guidelines: Global to local. <i>Annals of Thoracic Medicine</i> , 2009, 4, 161.	1.8	0
301	Statins in COPD. <i>Chest</i> , 2009, 136, 734-743.	0.8	125
302	Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoea–hypopnoea. <i>Sleep and Breathing</i> , 2009, 13, 241-252.	1.7	36
303	Economic burden of asthma: a systematic review. <i>BMC Pulmonary Medicine</i> , 2009, 9, 24.	2.0	580
304	Pediatric thyroid fine-needle aspiration cytology: a meta-analysis. <i>Journal of Pediatric Surgery</i> , 2009, 44, 2184-2191.	1.6	92
305	Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2009, 4, e6914.	2.5	346
306	Acetaminophen Use and the Risk of Asthma in Children and Adults. <i>Chest</i> , 2009, 136, 1316-1323.	0.8	124

#	ARTICLE	IF	CITATIONS
307	The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. <i>Quality of Life Research</i> , 2008, 17, 453-462.	3.1	64
308	Optimal decision criterion for detecting change in bone mineral density during serial monitoring: A Bayesian approach. <i>Osteoporosis International</i> , 2008, 19, 1589-96.	3.1	6
309	Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. <i>Arthritis and Rheumatism</i> , 2008, 59, 1690-1697.	6.7	1,181
310	Heteroscedastic Regression Analysis of Factors Affecting BMD Monitoring. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1842-1849.	2.8	6
311	Safety and Clinical Effectiveness of Midazolam versus Propofol for Procedural Sedation in the Emergency Department: A Systematic Review. <i>Academic Emergency Medicine</i> , 2008, 15, 1-8.	1.8	62
312	A Cost-effectiveness Analysis of Propofol versus Midazolam for Procedural Sedation in the Emergency Department. <i>Academic Emergency Medicine</i> , 2008, 15, 32-39.	1.8	29
313	Cost-Effectiveness of LTBI Treatment for TB Contacts in British Columbia. <i>Value in Health</i> , 2008, 11, 842-852.	0.3	15
314	Health State Utilities in Latent and Active Tuberculosis. <i>Value in Health</i> , 2008, 11, 1154-1161.	0.3	62
315	Inhaled Corticosteroids and the Risk of Fractures in Older Adults. <i>Drug Safety</i> , 2008, 31, 409-414.	3.2	41
316	Reliability studies of diagnostic tests are not using enough observers for robust estimation of interobserver agreement: a simulation study. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 722-727.	5.0	15
317	Letter to the Editor. <i>Vaccine</i> , 2008, 26, 5244.	3.8	1
318	Technical Note: Acceptability Curves Could Be Misleading When Correlated Strategies Are Compared. <i>Medical Decision Making</i> , 2008, 28, 306-307.	2.4	6
319	Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. <i>Thorax</i> , 2008, 63, 962-967.	5.6	47
320	Overdiagnosis of asthma in obese and nonobese adults. <i>Cmaj</i> , 2008, 179, 1121-1131.	2.0	335
321	Health-Related Quality of Life Trajectories Among Adults With Tuberculosis. <i>Chest</i> , 2008, 133, 396-403.	0.8	70
322	Asthma Worsenings: Approaches to Prevention and Management from the Asthma Worsenings Working Group. <i>Canadian Respiratory Journal</i> , 2008, 15, 1B-19B.	1.6	71
323	The Value of Bayes Theorem in the Interpretation of Subjective Diagnostic Findings: What Can We Learn from Agreement Studies?. <i>Medical Decision Making</i> , 2007, 27, 735-743.	2.4	5
324	Sample size requirements for bone density precision assessments and effect on patient categorization: A Monte Carlo simulation study. <i>Bone</i> , 2007, 41, 679-684.	2.9	1

#	ARTICLE	IF	CITATIONS
325	A New Approach for Quantifying Change and Test Precision in Bone Densitometry. <i>Journal of Clinical Densitometry</i> , 2007, 10, 365-369.	1.2	5
326	Resource Use Study in COPD (RUSIC): A prospective Study to Quantify the Effects of COPD Exacerbations on Health Care Resource Use Among COPD Patients. <i>Canadian Respiratory Journal</i> , 2007, 14, 145-152.	1.6	44
327	Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2554-2560.	2.8	357
328	Preferred skeletal site for osteoporosis screening in high-risk populations. <i>Public Health</i> , 2006, 120, 863-871.	2.9	10
329	Asthma Control in Canada Remains Suboptimal: The Reality of Asthma Control (TRAC) Study. <i>Canadian Respiratory Journal</i> , 2006, 13, 253-259.	1.6	187
330	Validity and reliability of a new food frequency questionnaire compared to 24-h recalls and biochemical measurements: pilot phase of Golestan cohort study of esophageal cancer. <i>European Journal of Clinical Nutrition</i> , 2006, 60, 971-977.	2.9	181
331	Obesity and hypertension in an Iranian cohort study; Iranian women experience higher rates of obesity and hypertension than American women. <i>BMC Public Health</i> , 2006, 6, 158.	2.9	110
332	Cost-effectiveness of Continuous Positive Airway Pressure Therapy for Moderate to Severe Obstructive Sleep Apnea/Hypopnea. <i>Archives of Internal Medicine</i> , 2006, 166, 977.	3.8	131
333	Cost-optimisation of screening for latent tuberculosis in close contacts. <i>European Respiratory Journal</i> , 2006, 28, 1285-1285.	6.7	0
334	Probabilistic Markov Model to Assess the Cost-Effectiveness of Bronchodilator Therapy in COPD Patients in Different Countries. <i>Value in Health</i> , 2005, 8, 32-46.	0.3	95
335	Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 366-370.	2.8	50
336	Discordance in diagnosis of osteoporosis using spine and hip bone densitometry. <i>BMC Endocrine Disorders</i> , 2005, 5, 3.	2.2	71
337	Artificial neural networks in prediction of bone density among post-menopausal women. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 425-431.	3.3	15
338	The CONCEPT trial: A 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. <i>Clinical Therapeutics</i> , 2005, 27, 393-406.	2.5	81
339	Adult Asthma Consensus Guidelines Update 2003. <i>Canadian Respiratory Journal</i> , 2004, 11, 9A-18A.	1.6	171
340	Reconcilable Differences. <i>Chest</i> , 2004, 126, 1161-1168.	0.8	27
341	Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: A 17-year experience. <i>BMC Neurology</i> , 2004, 4, 12.	1.8	34
342	Asthma. <i>Clinical Evidence</i> , 2003, , 1616-40.	0.2	0

#	ARTICLE	IF	CITATIONS
343	A Randomised Controlled Trial of High Dose, Inhaled Budesonide Versus Oral Prednisone in Patients Discharged from the Emergency Department following an Acute Asthma Exacerbation. Canadian Respiratory Journal, 2000, 7, 61-67.	1.6	54
344	Health Care Costs Associated with Acute Asthma: A Prospective Economic Analysis. Canadian Respiratory Journal, 1999, 6, 521-525.	1.6	17
345	Review: Magnesium sulfate is effective for severe acute asthma treated in the emergency department. ACP Journal Club, 1999, 131, 36.	0.1	1
346	Long-acting beta ₂ -agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease. The Cochrane Library, 0, , .	2.8	0
347	A Benefit-Harm Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. SSRN Electronic Journal, 0, , .	0.4	1
348	Clinical relevance of rheumatoid factor and anti-citrullinated peptides in fibrotic interstitial lung disease. Respirology, 0, , .	2.3	4